Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 5;33(3):1282-1299.
doi: 10.1016/j.ymthe.2025.01.041. Epub 2025 Jan 25.

A comprehensive atlas of AAV tropism in the mouse

Affiliations

A comprehensive atlas of AAV tropism in the mouse

Christopher J Walkey et al. Mol Ther. .

Abstract

Gene therapy with adeno-associated virus (AAV) vectors requires knowledge of their tropism within the body. Here we analyze the tropism of 10 naturally occurring AAV serotypes (AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh8, AAVrh10, and AAVrh74) following systemic delivery into male and female mice. A transgene-expressing ZsGreen and Cre recombinase was used to identify transduction in a cell-dependent manner based on fluorescence. Cre-driven activation of tdTomato fluorescence offered superior sensitivity for transduced cells. All serotypes except AAV3B and AAV4 had high liver tropism. Fluorescence activation revealed transduction of unexpected tissues, including adrenals, testes, and ovaries. Rare transduced cells within tissues were also readily visualized. Biodistribution of AAV genomes correlated with fluorescence, except in immune tissues. AAV4 was found to have a pan-endothelial tropism while also targeting pancreatic beta cells. This public resource enables selection of the best AAV serotypes for basic science and preclinical applications in mice.

Keywords: AAV; AAV tropism; adeno-associated virus; biodistribution; fluorescent reporter; gene therapy; mouse models; serotypes; transduction.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Update of

References

    1. Pupo A., Fernández A., Low S.H., François A., Suárez-Amarán L., Samulski R.J. AAV vectors: The Rubik's cube of human gene therapy. Mol. Ther. 2022;30:3515–3541. doi: 10.1016/j.ymthe.2022.09.015. - DOI - PMC - PubMed
    1. Wu Z., Asokan A., Samulski R.J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 2006;14:316–327. doi: 10.1016/j.ymthe.2006.05.009. - DOI - PubMed
    1. Rabinowitz J., Chan Y.K., Samulski R.J. Adeno-associated Virus (AAV) versus Immune Response. Viruses. 2019;11 doi: 10.3390/v11020102. - DOI - PMC - PubMed
    1. Zinn E., Vandenberghe L.H. Adeno-associated virus: fit to serve. Curr. Opin. Virol. 2014;8:90–97. doi: 10.1016/j.coviro.2014.07.008. - DOI - PMC - PubMed
    1. Greig J.A., Martins K.M., Breton C., Lamontagne R.J., Zhu Y., He Z., White J., Zhu J.X., Chichester J.A., Zheng Q., et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat. Biotechnol. 2024;42:1232–1242. doi: 10.1038/s41587-023-01974-7. - DOI - PMC - PubMed

LinkOut - more resources